1-3 of 3
Scott N. Gettinger
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors

Open Access
Adam J. Schoenfeld, Sylvia M. Lee, Bernard Doger de Spéville, Scott N. Gettinger, Simon Häfliger, Ammar Sukari, Sophie Papa, Juan F. Rodríguez-Moreno, Friedrich Graf Finckenstein, Rana Fiaz, Melissa Catlett, Guang Chen, Rongsu Qi, Emma L. Masteller, Viktoria Gontcharova, Kai He
Journal: Cancer Discovery
Cancer Discov (2024) 14 (8): 1389–1402.
https://doi.org/10.1158/2159-8290.CD-23-1334
Published: 02 August 2024
View articletitled, Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors
Open the PDF for Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors in another window
Includes: Supplementary data
Journal Articles

Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo

Available to Purchase
Giorgia Foggetti, Chuan Li, Hongchen Cai, Jessica A. Hellyer, Wen-Yang Lin, Deborah Ayeni, Katherine Hastings, Jungmin Choi, Anna Wurtz, Laura Andrejka, Dylan G. Maghini, Nicholas Rashleigh, Stellar Levy, Robert Homer, Scott N. Gettinger, Maximilian Diehn, Heather A. Wakelee, Dmitri A. Petrov, Monte M. Winslow, Katerina Politi
Journal: Cancer Discovery
Cancer Discov (2021) 11 (7): 1736–1753.
https://doi.org/10.1158/2159-8290.CD-20-1385
Published: 01 July 2021
View articletitled, Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo
Open the PDF for Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo in another window
Includes: Supplementary data
Journal Articles

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

Free
Adi Diab, Nizar M. Tannir, Salah-Eddine Bentebibel, Patrick Hwu, Vassiliki Papadimitrakopoulou, Cara Haymaker, Harriet M. Kluger, Scott N. Gettinger, Mario Sznol, Scott S. Tykodi, Brendan D. Curti, Mary A. Tagliaferri, Jonathan Zalevsky, Alison L. Hannah, Ute Hoch, Sandra Aung, Christie Fanton, Ahsan Rizwan, Ernesto Iacucci, Yijie Liao, Chantale Bernatchez, Michael E. Hurwitz, Daniel C. Cho
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2020) 10 (8): 1158–1173.
https://doi.org/10.1158/2159-8290.CD-19-1510
Published: 03 August 2020
View articletitled, Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Open the PDF for Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02) in another window
Includes: Supplementary data